Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

被引：11

作者：

Foss, Francine M. ^{[1
]}

Rubinowitz, Ami ^{[2
]}

Landry, Marie L. ^{[3
,4
]}

Isufi, Iris ^{[1
]}

Gowda, Lohith ^{[1
]}

Seropian, Stuart ^{[1
]}

Perreault, Sarah ^{[5
]}

Shenoi, Sheela V. ^{[6
]}

机构：

[1] Yale Univ, Sch Med, Hematol & Stem Cell Transplantat, 333 Cedar St, New Haven, CT 06510 USA

[2] Yale Sch Med, Radiol & Biomed Imaging, New Haven, CT USA

[3] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA

[4] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA

[5] Yale New Haven Hosp, Dept Pharm, 20 York St, New Haven, CT 06504 USA

[6] Yale Univ, Sch Med, Dept Med, Infect Dis, New Haven, CT 06510 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 11期

关键词：

Allogeneic stem cell transplantation; COVID-19; Graft-versus-host disease; Immunocompromised; JAK inhibitor; INHIBITION; JAK1;

D O I：

10.1016/j.clml.2020.06.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

引用

页码：720 / 723

页数：4

共 22 条

[21] The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China [J].

Zhang, Wen ;

Zhao, Yan ;

Zhang, Fengchun ;

Wang, Qian ;

Li, Taisheng ;

Liu, Zhengyin ;

Wang, Jinglan ;

Qin, Yan ;

Zhang, Xuan ;

Yan, Xiaowei ;

Zeng, Xiaofeng ;

Zhang, Shuyang .

CLINICAL IMMUNOLOGY, 2020, 214

[22]

Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI [10.1056/NEJMoa2001017, 10.1172/JCI89857]

← 1 2 3 →